Printer Friendly

BRISTOL-MYERS SQUIBB COMPANY ISSUES STATEMENT

 PRINCETON, N.J., July 2, /PRNewswire/ -- Bristol-Myers Squibb Company (NYSE: BMY) issued the following statement today regarding the U.S. District Court's June 30, 1993, decision in Bristol-Myers Squibb Company and Mead Johnson vs. Danbury Pharmacal, Inc., which held invalid a Mead Johnson buspirone patent:
 "Bristol-Myers Squibb believes that the court's decision to grant summary judgment was clearly erroneous as a matter of fact and law. The company intends to pursue vigorously preservation of its patent rights, will promptly appeal the decision and is confident it will prevail on appeal."
 Bristol-Myers Squibb filed suit on Sept. 16, 1992, alleging that Danbury infringed U.S. Patent No. 4,182,763 after Danbury had filed an Abbreviated New Drug Application with the Food and Drug Administration. U.S. Patent No. 4,182,763 was issued to Mead Johnson for use to treat neurotic anxiety in patients. Buspirone is marketed as BuSpar(R).
 /delval/
 -0- 7/2/93
 /CONTACT: Jane A. Kramer of Bristol-Myers Squibb, 609-252-5185, or home, 609-448-2233/
 (BMY)


CO: Bristol-Myers Squibb Company ST: New Jersey IN: MTC SU:

MK-JM -- PH009 -- 8094 07/02/93 10:44 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 2, 1993
Words:186
Previous Article:'OLD BEN' OUTPOINTS FELLOW CITIZENS IN MERIDIAN'S FINANCIAL LITERACY TEST DURING JULY FOURTH FREEDOM FEST ACTIVITIES
Next Article:PEACH BOTTOM SIREN TEST SCHEDULED FOR JULY 7
Topics:


Related Articles
BRISTOL-MYERS SQUIBB COMPANY WINS INJUNCTION FOR EXCEDRIN PM AGAINST TYLENOL PM
BRISTOL-MYERS SQUIBB COMPANY WINS APPEAL ON BUSPAR(R) PATENT INFRINGEMENT LAWSUIT
BRISTOL-MYERS SQUIBB FILES CLAIMS AGAINST CANADIAN COMPANY FOR MISREPRESENTATION OF ANTICANCER PRODUCT
Bristol-Myers Squibb and Pharmacopeia Form Research Alliance in Immunology/Inflammation
Bristol-Myers Squibb Medical Imaging and Kereos Enter Into Agreements to Develop Novel Molecular Imaging Agents.
Bristol-Myers Squibb Medical Imaging and IMCOR Pharmaceutical Co. Enter into Cross-Licensing Agreement for Ultrasound Contrast Patents.
Bristol-Myers Squibb and Medarex Global Development and Commercialization Collaboration for MDX-010 Becomes Effective.
Bristol-Myers Squibb Provides Regulatory Update for Muraglitazar and Abatacept.
Bristol-Myers Squibb Company and Medarex Form Global Development and Commercialization Collaboration for MDX-010.
Bristol-Myers Squibb Announces Agreement in Principle to Resolve Federal Antitrust Investigation.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters